SOURCE: Entest BioMedical Inc.

March 03, 2011 10:00 ET

Entest BioMedical Successfully Completes First ImenVax™ Cancer Vaccine Implantation in Canine Oncology Patient

First Canine Cancer Patient in ImenVax™ Safety Study Begins Treatment; Company Has Two More Dogs Ready for Near Term ImenVax™ Cancer Vaccine Procedure

SAN DIEGO, CA--(Marketwire - March 3, 2011) - Entest BioMedical Inc. (OTCQB: ENTB) announced today that on Wednesday (March 2, 2011), it successfully completed the implantation of its ImenVax™ immuno-therapeutic cancer vaccine in the first canine cancer patient as part of the ImenVax™ Canine Safety Study. The Company further stated that it has recruited two more dogs for the safety study that are expected to begin treatment over the next couple of weeks.

Chairman & CEO David Koos stated, "We are really excited about the accomplishment of this first major milestone in ImenVax™ development. To our knowledge, this is the first practical use of an implantable cancer vaccine in the veterinary setting. The Company anticipates that once all of the dogs involved with the ImenVax™ study have completed their treatment and demonstrated safety, ImenVax™ will become commercially available for treating dogs with cancer."

ImenVax™ is an immuno-therapeutic cancer vaccine being developed by the Company for the treatment of dogs with existing cancers which operates by utilizing the dog's own immune system to battle the cancer. ImenVax™ is intended to be a rapidly administered minimally invasive therapy which should not result in the deleterious side effects associated with chemotherapy and radiation therapy.

A Company spokesperson noted, "This represents a major advancement in treating canine oncology patients whose previous options were limited to high dose chemotherapy or euthanasia."

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCQB: ENTB) is a biotechnology company focused on the development of regenerative and immunological therapies for veterinary applications. The Company is specifically interested in veterinary therapies that harness the animal's own reparative and immunological mechanisms. Entest's products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). ImenVax™ utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure. Additionally, the Company is interested in acquiring veterinary hospitals as both a source of near term revenue and as a distribution channel for its veterinary therapies and treatments.


This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information